The association between cancer and PH: A tale of two diseases
A PVRI 2022 Digital webinar
Presentations
- Cancer induced PH: Embolism as a major inducer, Timothy Morris
- Cancer induced PH: Microenvironmental cancer niche as a major inducer, Rajkumar Savai
- Cancer therapies induced PH, Frédéric Perros
- Cancer related signalling mechanisms underlying PH development, Olivier Boucherat
- FOXO3: A new potential therapeutic target in pulmonary arterial hypertension, Yann Grobs
- Non-invasive surrogate markers of PH are associated with poor survival in lung cancer patients, Michael Cekay
Poll
Start of webinar poll
1. N/A
2. Talk 2: PH impacts the lung cancer prognosis and survival
Agree - 100%
Disagree - 0%
3. Talk 3: Current animal models of pulmonary hypertension, acute and hyperproliferative in nature, do not predict the effect of anti-cancer therapies in the setting
Yes - 100%
No - 0%
4. Talk 4: Should we focus on signaling pathways identified in cancer to find new actionable targets in PAH?
Yes - 100%
No - 0%
5. Talk 5: TFP is an antagonist of calmodulin and has a cardioprotective effect on left ventricle. In PAH, do you think TFP treatment could improve hemodynamic parameters by playing a role on lung and right ventricle maladaptive remodeling?
Yes - 75%
No - 25%
Talk 6: Lung cancer patients with pulmonary hypertension may profit from guidelines based pulmonary hypertension therapy.
Agree - 75%
Disagree - 25%